Loading...
XKRX
053030
Market cap349mUSD
Oct 02, Last price  
16,060.00KRW
Name

Binex Co Ltd

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
3.82
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-0.03%
Rev. gr., 5y
0.75%
Revenues
130.05b
-16.00%
55,128,608,54057,296,767,00071,138,024,95480,924,373,09778,026,379,736104,043,177,118125,258,578,553132,976,386,577134,399,279,256156,677,024,474154,824,775,515130,050,546,000
Net income
-35.07b
L
-7,444,788,270-4,069,080,780-6,812,622,549-3,004,864,364-11,294,772,9596,337,273,6568,504,132,8616,412,227,80019,094,152,20012,444,529,9304,670,748,390-35,070,821,000
CFO
-9.43b
L
-277,270,000-1,847,507,250-4,497,193,9693,798,796,9948,135,901,45413,560,867,77210,784,653,85019,853,740,08626,574,623,86417,062,098,0933,777,776,700-9,425,559,000
Dividend
Dec 29, 2008200 KRW/sh

Profile

BINEX Co., Ltd. operates as a pharmaceutical company in South Korea. It offers bisroot products; GI tract and antispasmodic, and antiulcer agents; NSAIDs; cardiovascular and urology products; hepatic protectors; ointments and creams; ophthalmic solutions; CNS agents; digestive products; constipation and blood circulation products; antibiotic and antifungal agents; cough and cold remedy products; vitamins and nutrients; antihistamine products; antivertigo products; and OTC products. BINEX Co., Ltd. has a co-development partnership with Genexine, Inc. to develop COVID-19 vaccine. The company was founded in 1957 and is based in Incheon, South Korea.
URL
http://www.bi-nex.co.kr/
IPO date
Aug 07, 2001
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
130,050,546
-16.00%
154,824,776
-1.18%
156,677,024
16.58%
Cost of revenue
145,746,711
153,285,038
126,125,354
Unusual Expense (Income)
NOPBT
(15,696,165)
1,539,737
30,551,670
NOPBT Margin
0.99%
19.50%
Operating Taxes
(3,747,349)
311,129
2,868,264
Tax Rate
20.21%
9.39%
NOPAT
(11,948,816)
1,228,608
27,683,406
Net income
(35,070,821)
-850.86%
4,670,748
-62.47%
12,444,530
-34.83%
Dividends
Dividend yield
Proceeds from repurchase of equity
(12,000,000)
BB yield
4.13%
Debt
Debt current
61,176,330
47,928,780
54,619,479
Long-term debt
11,022,938
12,332,550
3,065,087
Deferred revenue
Other long-term liabilities
688,902
754,767
1,257,563
Net debt
15,506,852
16,378,763
(29,370,108)
Cash flow
Cash from operating activities
(9,425,559)
3,777,777
17,062,098
CAPEX
(10,366,068)
(7,747,267)
(36,453,163)
Cash from investing activities
(2,853,403)
(14,179,951)
(39,124,800)
Cash from financing activities
29,840,754
(12,573,199)
3,223,216
FCF
(8,275,987)
(19,765,928)
7,273,392
Balance
Cash
27,793,022
13,453,694
38,203,107
Long term investments
28,899,394
30,428,873
48,851,566
Excess cash
50,189,889
36,141,328
79,220,822
Stockholders' equity
24,855,705
62,598,481
63,525,945
Invested Capital
223,244,020
199,445,975
182,968,319
ROIC
0.64%
15.03%
ROCE
0.65%
12.14%
EV
Common stock shares outstanding
31,134
32,497
30,925
Price
18,340.00
104.92%
8,950.00
-22.51%
11,550.00
-24.01%
Market cap
570,997,560
96.32%
290,845,751
-18.57%
357,178,391
-24.46%
EV
586,750,579
317,272,276
328,485,409
EBITDA
(3,263,978)
10,520,412
38,852,585
EV/EBITDA
30.16
8.45
Interest
2,296,389
2,061,625
Interest/NOPBT
6.75%